The field of cellular immunotherapies and stem cell transplantation is advancing rapidly as scientists discover new and better ways to harness the power of the immune system to fight cancer. These exciting new immunotherapies and transplant techniques are first available in clinical trials, which are research studies testing new treatments before they are commercially approved. These types of studies are typically only available at National Cancer Institute-designated cancer centers like Massey.
Clinical trials available through Massey’s Cellular Immunotherapies and Transplant Program include:
C-144-01: A phase 2, multicenter study to assess the efficacy and aafety of autologous tumor infiltrating lymphocytes (LN-144) for treatment of patients with metastatic melanoma
15-MMUD: A multi-center, phase 2 trial of HLA-mismatched unrelated donor bone marrow transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies
BMT-CTN-1101: A multi-center, phase 3, randomized trial of reduced intensity conditioning (RIC) and transplantation of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related bone marrow (haplo-BM) for patients with hematologic malignancies
E1910: A phase III randomized trial of blinatumomab for newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults